orciprenaline rapidly followed. 6 Although these drugs were effective in suppressing uterine activity, their therapeutic usefulness was somewhat compromised by their significant degree of cardiovascular {31 effects. A second generation of (32-selective sympathomimetic drugs was then developed, and included fenoterol, hexoprenaline, ritodrine, salbutamol and terbutaline. Hexoprenaline is said to have less effect on maternal heart rate,7 but otherwise at equivalent doses these drugs vary only in their biological half-lives. 8 A rare, but potentially life-threatening complication of these drugs is the occurrence of pulmonary oedema. The first case was published in 1977 9 and a total of 73 cases have been reported since then, with 7 deaths. A particularly high incidence (5070) has been reported in one series with the use of intravenous terbutaline. 1O 
LITERATURE REVIEW
Of the 73 cases of pulmonary oedema associated with {32-sympathomimetic treatment of premature labour which are reported or to which reference is made, only some are reported in detail. These cases involve terbutaline (24) , ritodrine (11) , isoxuprine (4), salbutamol (2) and fenoterol (4) . Most of the residual cases implicate fenoterol. Deaths (seven in all) have occurred with each of the above agents.
The reports involve oral, subcutaneous and continuous intravenous infusion of these drugs. No correlation was found with total dose administered or infusion rate. For example, total dose of salbutamol was between approximately 30 and 800 mg, yet in a recent report 30 1.2 g was infused with no ill effects. Pulmonary oedema has occurred with infusion of ritodrine at rates of 50-300 I-Ig/min. The initial starting infusion rate recommended is 50 to 100 I-Ig/min. 8 . In the 43 patients for whom adequate information is available, pulmonary oedema occurred before delivery in 29 (63070) . In these patients, duration of treatment with (32-sympathomimetic agents ranged from 6 to 96 hours. In 17 patients pulmonary oedema developed following delivery after the drug had been ceased for up to 11 hours, and one five days later. Three of the latter group developed pulmonary oedema after general anaesthesia (two for caesarean section and one for retained placenta) and two following epidural anaesthesia. Only three patjents required intermittent positive pressure ventilation for control of hypoxaemia, and at least two of these developed pulmonary oedema after general anaesthesia. Most of the other patients responded promptly to withdrawal of the tocolytic agent, oxygen administration and diuretic therapy, and symptoms and signs resolved within 24 hours.
The only maternal deaths reported in detail were associated with fenoterol; one lS developed pulmonary oedema 11 hours after cessation of fenoterol (post mortem examination showed myocarditis) and the other 21 five days after cessation of therapv. This second patient died at home on day 60 and necropsy was not reported, although the suggested clinical diagnosis was cardiomyopathy.
Twin pregnancy was present in 33070 of cases and steroids were administered concomitantly with a (3-agonist in 63%.
Of 21 patients for which fluid balance is recorded, there was a positive fluid balance of greater than one litre in 15.
Unfortunately, only four reported patients have been monitored with Swan Ganz catheters. Two patients who developed pulmonary oedema while receiving ritodrine by infusion 2s had normal pulmonary arterial and pulmonary artery wedge pressure values, and in another report pulmonary artery wedge pressure was also low (10 mmHg).13 However, in the only other published case with haemodynamic data, left ventricular filling pressure was high (32 mmHg).ls Thus three of four patients had normal or low pulmonary artery wedge pressure.
Thus, the syndrome of pulmonary oedema associated with (32-sympathomimetic therapy for premature labour bears no constant relationship to the drug used, route or rate of administration, total dose or duration of therapy. It may occur during treatment or after cessation of therapy and is of variable severity, but may be life-threatening. PATHOPHYSIOLOGY In the normal pulmonary circulation hydrostatic and osmotic forces are in such balance that the fluid passing from the pulmonary capillaries to the interstitium is easily removed by the lymphatics of the lung. When the left ventricle is unable to pump the blood returned to it, left atrial pressure rises, which increases pulmonary capillary hydrostatic pressure causing a net movement of fluid into the pulmonary interstitial space. This can occur from alterations of any of the determinants of left ventricular function: increased preload (fluid overload), decreased contractility (myocardial infarction or cardiomyopathy), or increased afterload (severe hypertension or vasoconstriction). When the influx of fluid to the insterstitium exceeds efflux, clinical pulmonary oedema results.
Non-cardiogenic pulmonary oedema also involves an imbalance of the same Starling forces. With this condition, however, the primary change is an increase in capillary permeability. The result again is a net movement of fluid into the lungs, but in this condition alveolar fluid is protein-rich. 31 Acute pulmonary oedema is an infrequently reported but potentially fatal complication of pregnancy. It usually appears in the third trimester or during labour in association with the severe hypertension of pre-eclampsia.
Pulmonary oedema occurring earlier than the third trimester usually results from pre-existing cardiac disease and, like the pulmonary oedema (32-TOCOL YTIC-ASSOCIATED PULMONARY OEDEMA of pre-eclampsia and fluid overload, is secondary to left ventricular failure. Noncardiogenic or permeability pulmonary oedema may occur after aspiration of gastric contents, amniotic fluid embolism and other obstetric disasters causing disseminated intravascular coagulation such as abruptio placentae or transfusion reactions.
Various mechanisms have been proposed for the pulmonary oedema associated with (32-sympathomimetic therapy. These include fluid overload,16,18 catecholamine-related myocardial necrosis 21 and cardiac failure secondary to tachycardia,18 which would cause cardiogenic pulmonary oedema, and a direct effect of the drug on the pulmonary capillary membrane which would lead to noncardiogenic pulmonary oedema. 13, 23, 28 Although cardiogenic and non-cardiogenic pulmonary oedema often occur as distinct pathophysiological and clinical entities, it is possible they may coexist.
P ATHOGENESIS
In an attempt to further elucidate the pathogenesis of pulmonary oedema associated with the use of (32-sympathomimetic agents as treatment for premature labour, the likely contributing causes are reviewed.
(1) Previously undiagnosed heart disease
It is well known that pregnancy may worsen heart disease already present or unmask a previously unsuspected cardiac abnormality,
In six reports of pulmonary oedema associated with the use of (32-sympathomimetics for premature labour, pre-existing cardiovascular disease was present. In one patient mild mitral insufficiency and left atrial enlargement were diagnosed two days later, 24 and in another, moderate maternal preeclampsia was present. 17 Two patients had unsuspected mitral valve prolapse at echocardiographY,lo,22 one an asymptomatic atrial septal defect 30 and another a past history of rheumatic fever with a normal follow-up echocardiogram. 1o
In most cases, however, follow-up echocardiography and phonocardiography were normal and pre-existing heart disease was excluded.
Primary myocardial disease developing during the course of pregnancy or in the first five months after pregnancy is rare, representing less than 1070 of the cardiovascular problems associated with pregnancy. 32 Patients with peripartum cardiomyopathy typically present with symptoms and signs of congestive cardiac failure in the absence of any known previous medical illness.
However, the rapid clinical improvement shown by patients after withdrawal of (32-tocolytic agents and administration of diuretics would tend to exclude the diagnosis of peripartum cardiomyopathy. Viral studies, cardiac catheterisation or endomyocardial biopsy were, however, not performed in any reported cases. It is most unlikely that the pulmonary oedema associated with (3-adrenergic agents is simply an association between a rare disease and a widely prescribed medication, (2) The normal hyperdynamic and hypervolaemic state of pregnancy Pregnancy itself imposes considerable stress on the heart and circulation. The cardiovascular adaptations of normal pregnancy are shown in Figure 1 . Labour may also produce sudden and profound changes which can be exaggerated by apprehension, particularly when labour occurs before term. There is a dose-related increase in maternal heart rate. 8 In most cases it is possible to distinguish a distinct secondary peak in pulse rate one to two minutes after the primary peak after an intravenous bolus injection. 7 The primary peak probably arises from a direct effect of the drug on the cardiac fJl-receptors and the secondary peak is most likely due to a baroreceptor-induced reflex adjustment in response to peripheral vasodilatation. There is a close correlation between the time of onset of the uterine-inhibitory effect and the time of increase in maternal pulse rate. 8 When infused in pregnant women, there is little change in mean blood pressure with any of the fJ2-sympathomimetic agents. Ritodrine causes a marked fall in peripheral vascular resistance demonstrated by polyplethysmography35 and when calculated by dividing mean blood pressure by cardiac output. 36 It is likely the other agents have similar effects.
There is also a consistent increase in cardiac output, which, with ritodrine, has been demonstrated to rise 56070 above control values at 40 minutes. 36 The effects of terbutaline on left ventricular size and performance in pregnant women with premature labour have been demonstrated by M-mode echocardiography.27 Cardiac output increased from 7 to 9.5 lImin and ejection fraction also increased significantly. In this study it was concluded that terbutaline is a potent inotropic as well as chronotropic agent.
(4) Specific effects of catecholamines
It is possible that the prolonged administration of salbutamol and other tocolytic agents may produce left ventricular failure and pulmonary oedema purely due to its action as a fJ-adrenergic agonist. In the rabbit heart, fJ2-adrenoreceptors constitute only 5-7% of the total fJ-adrenoreceptor population in the ventricles, r.nd 28% and 18% in the right and left atria respectively. 37 However, in a study of contractility in isolated cat ventricular muscle, terbutaline was shown to act as a partial agonist at the fJl-receptor. 38 Thus salbutamol and other fJ2-agonists may act directly on the heart at the fJl-receptor a~ well as the fJ2-receptor.
Prolonged administration of salbutamol could then lead to cardiac failure in two ways. First, myocardial lesions have been described in patients who have received catecholamines for prolonged periods before death,39 and similar lesions have been produced in the myocardium of laboratory animals by the administration of adrenaline and noradrenaline. These are described as myocardial fibrotic and degenerative lesions and have been observed in the hearts of 58% of 26 patients with phaeochromocytoma. 40 They are possibly due to an imbalance between increased oxygen requirements and limited adjustment in coronary blood flow.
This mechanism seems unlikely as follow-up cardiovascular assessment was normal in most patients. However, the clinically recognised cardiomyopathy, presumably related to catecholamines in association with phaeochromocytoma, subsides clinically after resection of the tumour, and follow-up in these patients is also normal. 40 Thus patients who develop pulmonary oedema during treatment with f32-adrenergic agents for premature labour may develop a reversible cardiomyopathy secondary to a catecholamine-like action on the heart. Fenoterol can induce necrosis experimentally in human foetal hearts,41 an effect which is reversible by the calcium antagonist verapamil. Thus it is possible that betamimetics themselves can induce cardiac failure with overdose.
The second, and perhaps more attractive, proposed mechanism attributed to a direct adrenergic effect on the heart, involves the concept of "down-grading of receptors".
f3-adrenergic agents are assumed to act by initially binding to receptors on target cell plasma membranes, thereby activating adenylate cyclase and stimulating generation of cyclic AMP. 42 But they also have a second action -regulation of responsiveness of the target cells. This self-regulation of target cell responsiveness, variously termed refractoriness, desensitisation and downregulation, has been observed with catecholamines. Several experimental models have suggested this may be due to a decrease in the number of membrane receptors for the amines and indirect studies in man also support this. For example, normal and asthmatic subjects who are treated chronically with adrenergic agonists have decreased bronchodilatation and diminished generation of leucocyte cyclic AMP in response to catecholamines; 42 decreased numbers of f3-adrenergic receptors. Interestingly, corticosteroids also decrease the number of f3-adrenergic receptors. 44 Recently, it has been suggested that downregulation of f3-receptors after chronic exposure to high concentrations of catecholamines may be a contributory mechanism in patients with severe heart failure, by depriving the heart of needed adrenergic support. 45 Decreased catecholamine sensitivity and f3-adrenergic receptor density has been demonstrated in failing human hearts. 46 This mechanism could be a major contributing factor in the pathogenesis of pulmonary oedema associated with prolonged f3-adrenergic and corticosteroid administration in premature labour, particularly in the patients who develop the syndrome after withdrawal of the drug, and after general anaesthesia and administration of myocardial depressant agents.
Apart from their actions on the heart, catecholamines have potent effects on the peripheral and pulmonary vasculature. Pulmonary oedema has been reported following inadvertent injection of large doses of adrenaline 47 and recurrent acute noncardiogenic pulmonary oedema occurred in a young patient with phaeochromocytoma. 48 It has been widely suggested that neurogenic pulmonary oedema results from a centrally mediated sympathetic discharge. However, in rabbits with experimental neurogenic pulmonary oedema,49 this effect was blocked with dibenzyline, an a-adrenergic blocker, and it is therefore extremely unlikely that salbutamol and other f32-adrenergic agonists could directly produce pulmonary oedema in this way.
Transient hypertension has not been described as a complication of betamimetic therapy. On the contrary, reduction in systemic mean arterial pressure occurs frequently, due to peripheral vasodilatation. This afterloadreducing effect has been used therapeutically and salbutamol has been used in the treatment of severe cardiac failure and cardiogenic shock; in doses of 10-40 J..Ig/min, it has been found to benefit patients with severe congestive cardiomyopathy,50 after cardiac surgery, 51 severe heart failure 52 and cardiogenic shock complicating acute myocardial infarction. 53
These infusion rates are similar to those used in pregnant patients who have developed pulmonary oedema, but caused no adverse effects in these patients with cardiac failure.
(5) Fluid overload
The large diuresis with treatment of the pulmonary oedema in many reported cases is noteworthy, especially as in most cases it was associated with a dramatic clinical improvement and resolution of the chest X-ray changes of pulmonary oedema. In some cases strong positive fluid balances have been reported immediately prior to the development of respiratory distress,19,26 but in others the fluid retention appears to be more chronic. Blood volume is already increased in pregnancy by 40-6011,10 above non-pregnant values. 33 Administration of f3-sympathomimetic agents which cause vasodilatation and increased cardiac output may cause a further increase in circulating blood volume; and f3-adrenergic agents have been shown to be associated with an increase in the concentration of antidiuretic hormone in water-loaded normal subjects. 54 Water retention reflected by an increase in weight of 1-2 kg has been noted after 48 hours of intravenous infusion of f3-sympathomimetics despite fluid restriction. 55 The contribution of corticosteroid administration to this fluid retention is unclear. Betamethasone and dexamethasone have little or no mineralocorticoid salt-and waterretaining effects in normal man, but their effects in pregnancy are unknown. Certainly, in many (60%) of the reported cases of pulmonary oedema associated with f32-sympathomimetic therapy for premature labour, corticosteroids were administered. Uncontrolled fluid administration was noted in several reports. 18
(6) Indomethacin
It has been suggested that indomethacin might play a contributory role in the pathogenesis of the syndrome.
Prostaglandins are known to play an important part in the onset of labour and in vitro experiments 56 have shown that oxytocininduced contractions of rat uterus can be prevented by indomethacin. However, indomethacin accentuates the capillary permeability of endotoxin in sheep,57 possibly by increasing the formation of the chemotactic products of the lipoxygenase pathway of arachidonic acid metabolism. Such an effect could be a contributory factor in the pathogenesis of pulmonary oedema in this syndrome.
Treatment with indomethacin may also contribute to sodium and water retention. 58 (7) Other factors
The most serious cases of pulmonary oedema have occurred after general anaesthesia. It has been recommended 59 that halothane should be avoided in patients receiving f3-sympathomimetics because of its myocardial depressant properties and sensitisation of the heart to f3-agonists.
It is conceivable that even minimal myocardial depression due to anaesthetic agents in the presence of a hyperdynamic circulation secondary to pregnancy and sympathomimetic agents could precipitate cardiac failure.
Ergometrine administration was associated with pulmonary oedema in a patient receiving salbutamol. 15 It is likely that vasoconstriction in the dilated vascular compartment precipitated pulmonary oedema. Ergometrine should clearly be avoided in these circumstances.
Other contributing factors include the anaemia of pregnancy which may increase the high output state by decreasing the already low peripheral resistance by reducing blood viscosity. 60 Colloid osmotic pressure l1as been demonstrated to decrease from 25 to 19 mmHg with long-term betamimetic therapy. 55 This could contribute to an imbalance of Starling forces, but is unlikely to be the sole mechanism.
(8) A direct effect of the drug on the pulmonary capillary membrane
A direct effect of the drug on the pulmonary capillary membrane is also possible. In a study of mongrel dogs given infusions of fenoterol,61 the development of interstitial oedema corresponded with massive shifts of lung fluids from the intravascular to the extravascular space as measured by a thermo-dye technique.
However, in a study on lung fluid balance during air emboli in awake sheep, terbutaline appeared to decrease lung lymph and protein flow. 62 This was thought to be due to the decrease in pulmonary vascular pressures, rather than a "protective" effect on the pulmonary capillary membrane.
Although increased capillary permeability has been suggested by several authors,13,28 no possible mechanism has been proposed, apart from "an individual idiosyncratic response to the drug".
(3-agonists are known to stimulate lipolysis and increase serum-free fatty acids. An analogy can be drawn with the fat embolism syndrome, in that, in the fulminant pulmonary oedema associated with (3-agonists and adult respiratory distress syndrome (ARDS) is severe, but recovery is complete and the attack rate is low, Free fatty acids in this condition are thought to moderate the pulmonary capillary inj ury63 and disturbances in lipid metabolism have been demonstrated in follow-up studies. 64 When increased pulmonary capillary permeability occurs during (3-sympathomimetic treatment, it might possibly be due to increased circulating free fatty acids.
RECOMMENDATIONS
In discussing recommendations on the screening, monitoring and treatment of complications of patients treated with (32-adrenergic agents, it is necessary to comment on the rationale for their use.
Preterm delivery is responsible for about 70-;0 of all births, but accounts for 750-;0 of perinatal mortality. 65 Many drugs have been claimed to suppress premature labour. However, a recent review 66 looked at 18 clinical trials of hormones, alcohol or (3-sympathomimetic agents. In only two was the drug found more effective than placebo in postponing delivery and a favourable effect in terms of foetal outcome was found in only one. Placebo is said to arrest premature labour in 600-;0 of patients. 14 The tacit assumption that inhibiting preterm labour is necessarily beneficial should not go unchallenged. Indeed, preterm labour may often be nature's best option in the presence of foetal, placental or maternal abnormality, and it has been suggested that only 100-;0 of patients in early or suspected premature labour can even theoretically profit from tocolytic agents. 14 Perhaps then, it is not surprising that the incidence of infants with birth weight of less than 2,500 g is unchanged over the past three decades with or without tocolytic agents; and in West Germany alone,9 one million ampoules and six million tablets of fenoterol are said to AnueSfhesta and Intellsive Cure, Vol. 12, No, 2, May, 1984 be used each year without, however, any fall in the number of infants of low birth weight.
It must be concluded that these agents are generally overused.
If treatment with (3-sympathomimetic agents is deemed appropriate, screening should include a detailed history and examination aimed at excluding the possibility of maternal cardiac disease, weight, serum electrolytes and glucose, full blood count and baseline ECG.
Monitoring during therapy must consist of strict measurement of fluid balance with daily weighing, regular monitoring of pulse rate, blood pressure, respiratory rate and urine output and routine measurement of serum potassium, blood glucose and haematocrit.
In particular, the development of pulmonary oedema should be anticipated especially in the presence of other factors which seem to increase risk. 67 These are twin pregnancy, the use of corticosteroids, positive fluid balance, a maternal pulse rate sustained above 140 per minute for prolonged periods and general anaesthesia. Treatment with (32-agonists should only take place in centres where facilities for maternal resuscitation exist.
The pathogenesis of this syndrome is multifactorial. The hyperdynamic and hypervolaemic circulation of normal pregnancy and labour is accentuated by the action of (3-agonist drugs. Decompensation in the form of left ventricular failure and pulmonary oedema may occur under circumstances of fluid overload or retention (iatrogenic, corticosteroids, indomethacin), myocardial depression (general anaesthesia, receptor downgrading) or peripheral vasoconstriction (ergometrine).
A direct toxic effect on the heart cannot be excluded. Increased pulmonary capillary permeability occurs in some patients with fulminant pulmonary' oedema, but the mechanism is unknown.
If detected early, pulmonary oedema is usually adequately and completely treated by cessation of (32-sympathomimetic therapy, oxygen administration and diuretics.
The more fulminant form with characteristics of ARDS is more common after general anaesthesia and requires sophisticated ventilatory support and invasive haemodynamic monitoring.
In view of the recent interest in the use of f32-sympathomimetic drugs as treatment for ARDS, further investigation is essential to determine whether these agents cause or predispose to pulmonary microvascular injury.
